Literature DB >> 4429965

Effect of route of administration and effusions on methotrexate pharmacokinetics.

S H Wan, D H Huffman, D L Azarnoff, R Stephens, B Hoogstraten.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4429965

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  28 in total

1.  Variability of oral bioavailability for low dose methotrexate in rats.

Authors:  T Kuroda; K Namba; T Torimaru; S Yamamoto; M Akahori
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

Review 2.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

3.  Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.

Authors:  Karen D Wright; John C Panetta; Arzu Onar-Thomas; Wilburn E Reddick; Zoltan Patay; Ibrahim Qaddoumi; Alberto Broniscer; Giles Robinson; Frederick A Boop; Paul Klimo; Deborah Ward; Amar Gajjar; Clinton F Stewart
Journal:  Cancer Chemother Pharmacol       Date:  2014-10-24       Impact factor: 3.333

Review 4.  Clinical pharmacokinetics of methotrexate.

Authors:  D D Shen; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

5.  The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis.

Authors:  P Seideman; O Beck; S Eksborg; M Wennberg
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

6.  Competitive protein binding assay for methotrexate.

Authors:  C E Myers; M E Lippman; H M Elliot; B A Chabner
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

7.  Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukaemia.

Authors:  P J Kearney; P A Light; A Preece; M G Mott
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 8.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

9.  Effects of polysorbate 80 on the absorption and distribution of oral methotrexate (MTX) in mice.

Authors:  M N Azmin; J F Stuart; K C Calman; A T Florence
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Clinical pharmacology of oral intermediate-dose methotrexate with or without probenecid.

Authors:  M B Lilly; G A Omura
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.